Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 41

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 41
---
| ● | regulatory developments; |

| ● | fluctuations in our quarterly or annual operating results; |

| ● | passage of legislation                                                                                                                  
 or other regulatory developments affecting us or our industry changes in expectations as to our future financial performance, including 
 financial estimates by securities analysts and investors, or differences between our actual results and those expected by investors     
 and securities analyst;                                                                                                                 |

| ● | additions or departures of key personnel; and |

| ● | future sales of our Common Stock or other securities. |

Sales of substantial amounts of our Common Stock,
or in anticipation that such sales could occur, may materially and adversely affect prevailing market prices for our Common Stock, if
and when such a market develops in the future.

The price at which you purchase shares of our
Common Stock may not be indicative of the price that will prevail in the trading market. You may be unable to sell your shares of Common
Stock at or above your purchase price, which may result in substantial losses to you and which may include the complete loss of your investment.
In the past, securities class action litigation has often been brought against a company following periods of stock price volatility.
We may be the target of similar litigation in the future. Securities litigation could result in substantial costs and divert management’s
attention and our resources away from our business. Any of the risks described above could adversely affect our sales and profitability
and the price of our Common Stock.

<div align='center'>21</div>

The requirements of becoming an SEC reporting public company may strain our resources, divert management’s attention and affect our ability to attract and retain executive management and qualified board members.

Once we become an SEC
reporting public company, we will be subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, and the
Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Act, and other applicable securities rules and regulations. Compliance with these
rules and regulations increases our legal and financial compliance costs, make some activities more difficult, time-consuming or costly,
and increase demand on our systems and resources, particularly after we are no longer an “emerging growth company,” as defined
in the Jumpstart our Business Startups Act, or the JOBS Act. The Exchange Act requires, among other things, that we file annual, quarterly
and current reports with respect to our business and operating results. The Sarbanes-Oxley Act requires, among other things, that we maintain
effective disclosure controls and procedures and internal